Clinical and pharmacological group: & nbsp
Nootropics
Included in the formulation
АТХ:N.06.B.A Sympathomimetics of central action
N.06.B.A.09 Atomoxetine
Pharmacodynamics:A selective inhibitor of the transport systems of presynaptic endings, blocks the reverse neuronal capture. Does not apply to psychostimulants.
Pharmacokinetics:After oral intake absorbed in the gastrointestinal tract almost completely. The maximum concentration in the blood plasma is achieved in 1-2 hours. Metabolized in the liver with the participation of cytochrome CYP2D6. The active 4-hydroxyatomoxetine metabolite undergoes rapid glucuronization.
Half-Elimination (half-life) of the drug is 3 hours. In patients with reduced metabolism - up to 21 hours.
Elimination by the kidneys in 80%, in 17% - with feces, in an unchanged form no more than 3%. It is not removed during hemodialysis.
Indications:It is used for attention deficit hyperactivity disorder in children aged 6 years, adolescents and adults.
V.F90-F98.F90.0 Violation of activity and attention
Contraindications:Closed-angle glaucoma, administration of MAO inhibitors.
Individual intolerance.
Carefully:Patients with impaired liver function are recommended to use the amount of the drug at 50% below the usual dose.
Pregnancy and lactation:Recommendations for Food and Drug Administration (US Food and Drug Administration) - С. The drug is not used in pregnancy and lactation.
Dosing and Administration:It is used once a day, regardless of food intake, in the morning.
From 6 to 18 years with a body weight of less than 70 kg is used in an amount of 500 mg / kg per day, with a gradual increase in the dose to 1.8 μg / kg per day for 204 weeks. The maintenance dose is 1.2 μg / kg per day.
Children and adolescents with a body weight exceeding 70 kg receive an initial dose of 40 mg, with an increase to 80 mg for 3 days. If necessary, the daily dose rises to 120 mg per day. Supportive dose of 80 mg per day.
The highest daily dose: children - 1,8 mkg / kg per day, adults - 120 mg per day.
The highest single dose: children - 1,8 mkg / kg per day, adults - 120 mg per day.
Side effects:Central and peripheral nervous system: dizziness, early morning awakening and drowsiness during the day, emotional lability, suicidal tendencies.
Cardiovascular system: sinus tachycardia.
System of analyzers: mydriasis.
Digestive system: abdominal pain, dyspeptic disorders.
Metabolic system: decreased appetite until anorexia, weight loss.
Genitourinary and reproductive system: delay urination, dysmenorrhea, sexual dysfunction - violation of orgasm, ejaculation and erection.
Allergic reactions.
Overdose:Excitation, tachycardia, dry mouth, convulsive syndrome.
Treatment is symptomatic.
Interaction:Enhances the effect of midazolapam.
Increased risk of developing hypertension with simultaneous use of the drug with vasopressors.
When taking inhibitors of CYP2D6: paroxetine, fluoxetine, quinidine - it is necessary to reduce the dose of atomoxetine.
An increase in side effects occurs with simultaneous administration with salbutamol.
The intake of MAO inhibitors and atomoxetine should be separated by a gap of at least 2 weeks.
Special instructions:The drug does not cause addiction and any dependence. Stopping the intake of atomoxetine does not require a gradual reduction in dosages.
Reception of the drug is sometimes accompanied by drowsiness, it is recommended to take care of drivers and persons working with mechanical moving objects.